The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Sharlai A.S.

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

Sidorov I.V.

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

Konovalov D.M.

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology;
Russian Medical Academy for Continuous Professional Education

Characteristics of the cytogenetic variants of alveolar rhabdomyosarcoma

Authors:

Sharlai A.S., Sidorov I.V., Konovalov D.M.

More about the authors

Read: 1263 times


To cite this article:

Sharlai AS, Sidorov IV, Konovalov DM. Characteristics of the cytogenetic variants of alveolar rhabdomyosarcoma. Russian Journal of Archive of Pathology. 2024;86(6):21‑27. (In Russ.)
https://doi.org/10.17116/patol20248606121

References:

  1. WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. 5th ed. Vol. 3. Lyon, France: International Agency for Research on Cancer; 2020.
  2. Agaram NP. Evolving classification of rhabdomyosarcoma. Histopathology. 2022;80(1):98-108.  https://doi.org/10.1111/his.14449
  3. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, eds. WHO classification of tumours of soft tissue and bone. 4th ed. Vol. 5. Lyon: IARC; 2013.
  4. Shern JF, Selfe J, Izquierdo E, Patidar R, Chou HC, Song YK, Yohe ME, Sindiri S, Wei J, Wen X, et al. Genomic classification and clinical outcome in rhabdomyosarcoma: a report from an International Consortium. J Clin Oncol. 2021;39(26):2859-2871. https://doi.org/10.1200/JCO.20.03060
  5. Shulman DS, Whittle SB, Surdez D, Bailey KM, de Álava E, Yustein JT, Shlien A, Hayashi M, Bishop AJ, Crompton BD, et al. An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. NPJ Precis Oncol. 2022;6(1):65.  https://doi.org/10.1038/s41698-022-00307-2
  6. Alaggio R, Zhang L, Sung YS, Huang SC, Chen CL, Bisogno G, Zin A, Agaram NP, LaQuaglia MP, Wexler LH, et al. A molecular study of pediatric spindle and sclerosing rhabdomyosarcoma: identification of novel and recurrent VGLL2-related fusions in infantile cases. Am J Surg Pathol. 2016;40(2):224-235.  https://doi.org/10.1097/PAS.0000000000000538
  7. Mosquera JM, Sboner A, Zhang L, Kitabayashi N, Chen CL, Sung YS, Wexler LH, LaQuaglia MP, Edelman M, Sreekantaiah C, et al. Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosomes Cancer. 2013;52(6):538-550.  https://doi.org/10.1002/gcc.22050
  8. Agaram NP, Zhang L, Sung YS, Cavalcanti MS, Torrence D, Wexler L, Francis G, Sommerville S, Swanson D, Dickson BC, et al. Expanding the spectrum of intraosseous rhabdomyosarcoma: correlation between 2 distinct gene fusions and phenotype. Am J Surg Pathol. 2019;43(5):695-702.  https://doi.org/10.1097/PAS.0000000000001227
  9. Xu B, Suurmeijer AJH, Agaram NP, Zhang L, Antonescu CR. Head and neck rhabdomyosarcoma with TFCP2 fusions and ALK overexpression: a clinicopathological and molecular analysis of 11 cases. Histopathology. 2021;79(3):347-357.  https://doi.org/10.1111/his.14323
  10. Barr FG, Qualman SJ, Macris MH, Melnyk N, Lawlor ER, Strzelecki DM, Triche TJ, Bridge JA, Sorensen PH. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. Cancer Res. 2002:62(16):4704-4710.
  11. Sumegi J, Streblow R, Frayer RW, Dal Cin P, Rosenberg A, Meloni-Ehrig A, Bridge JA. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. Genes Chromosomes Cancer. 2010;49(3):224-236.  https://doi.org/10.1002/gcc.20731
  12. Liu J, Guzman MA, Pezanowski D, Patel D, Hauptman J, Keisling M, Hou SJ, Papenhausen PR, Pascasio JM, Punnett HH, et al. FOXO1-FGFR1 fusion and amplification in a solid variant of alveolar rhabdomyosarcoma. Mod Pathol. 2011;24(10):1327-1335. https://doi.org/10.1038/modpathol.2011.98
  13. Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014;4(2):216-231.  https://doi.org/10.1158/2159-8290.CD-13-0639
  14. Panferova A, Sinichenkova KY, Abu Jabal M, Usman N, Sharlai A, Roshchin V, Konovalov D, Druy A. EWSR1-TFCP2 in an adolescent represents an extremely rare and aggressive form of intraosseous spindle cell rhabdomyosarcomas. Cold Spring Harb Mol Case Stud. 2022;8(5):a006209. https://doi.org/10.1101/mcs.a006209
  15. Dehner CA, Broski SM, Meis JM, Murugan P, Chrisinger JSA, Sosa C, Petersen M, Halling KC, Gupta S, Folpe AL. Fusion-driven spindle cell rhabdomyosarcomas of bone and soft tissue: a clinicopathologic and molecular genetic study of 25 cases. Mod Pathol. 2023;36(10):100271. https://doi.org/10.1016/j.modpat.2023.100271
  16. Smith BF, Doung YC, Beckett B, Corless CL, Davis LE, Davis JL. Intraosseous spindle cell rhabdomyosarcoma with MEIS1::NCOA2 fusion — case report with substantial clinical follow-up and review of the literature. Cancer Invest. 2023;41(8):704-712.  https://doi.org/10.1080/07357907.2023.2255668
  17. Bradová M, Mosaieby E, Michal M, Vaněček T, Ing SK, Grossmann P, Koshyk O, Kinkor Z, Laciok Š, Nemcová A, et al. Spindle cell rhabdomyosarcomas: with TFCP2 rearrangements, and novel EWSR1::ZBTB41 and PLOD2::RBM6 gene fusions. A study of five cases and review of the literature. Histopathology. 2024;84(5):776-793.  https://doi.org/10.1111/his.15121
  18. Skapek SX, Ferrari A, Gupta AA, Lupo PJ, Butler E, Shipley J, Barr FG, Hawkins DS. Rhabdomyosarcoma. Nat Rev Dis Primers. 2019;5(1):1.  https://doi.org/10.1038/s41572-018-0051-2
  19. Reichek JL, Duan F, Smith LM, Gustafson DM, O’Connor RS, Zhang C, Dunlevy MJ, Gastier-Foster JM, Barr FG. Genomic and clinical analysis of amplification of the 13q31 chromosomal region in alveolar rhabdomyosarcoma: a report from the Children’s Oncology Group. Clin Cancer Res. 2011;17(6):1463-1473. https://doi.org/10.1158/1078-0432.CCR-10-0091
  20. Barr FG, Duan F, Smith LM, Gustafson D, Pitts M, Hammond S, Gastier-Foster JM. Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: a report from the Children’s Oncology Group. Genes Chromosomes Cancer. 2009;48(8):661-672.  https://doi.org/10.1002/gcc.20673
  21. Anderson J, Gordon A, Pritchard-Jones K, Shipley J. Genes, chromosomes, and rhabdomyosarcoma. Genes Chromosomes Cancer. 1999;26(4):275-285. 
  22. Gordon AT, Brinkschmidt C, Anderson J, Coleman N, Dockhorn-Dworniczak B, Pritchard-Jones K, Shipley J. A novel and consistent amplicon at 13q31 associated with alveolar rhabdomyosarcoma. Genes Chromosomes Cancer. 2000;28(2):220-226. 
  23. Duan F, Smith LM, Gustafson DM, Zhang C, Dunlevy MJ, Gastier-Foster JM, Barr FG. Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the Children’s Oncology Group. Genes Chromosomes Cancer. 2012;51(7):662-674.  https://doi.org/10.1002/gcc.21953
  24. Missiaglia E, Williamson D, Chisholm J, Wirapati P, Pierron G, Petel F, Concordet JP, Thway K, Oberlin O, Pritchard-Jones K, et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol. 2012;30(14):1670-1677. https://doi.org/10.1200/JCO.2011.38.5591
  25. Selfe J, Olmos D, Al-Saadi R, Thway K, Chisholm J, Kelsey A, Shipley J. Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: retrospective analyses of patients on UK trials. Pediatr Blood Cancer. 2017;64(7):e26386. https://doi.org/10.1002/pbc.26386
  26. Williamson D, Missiaglia E, de Reyniès A, Pierron G, Thuille B, Palenzuela G, Thway K, Orbach D, Laé M, Fréneaux P, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol. 2010;28(13):2151-2158. https://doi.org/10.1200/JCO.2009.26.3814
  27. Alaggio R, Kelsey A, Bailey KM, Bisogno G, Davis J, Dry SM, Konovalov D, Lazar A, O’Sullivan M, Rudzinski E, et al. Paediatric rhabdomyosarcoma histopathology reporting guide. 1st ed. Sydney, Australia: International Collaboration on Cancer Reporting; 2023.
  28. Gagnon MF, Pearce KE, Greipp PT, Xu X, Hoppman NL, Ketterling RP, McPhail ED, King RL, Baughn LB, Peterson JF. MYC break-apart FISH probe set reveals frequent unbalanced patterns of uncertain significance when evaluating aggressive B-cell lymphoma. Blood Cancer J. 2021;11(11):184.  https://doi.org/10.1038/s41408-021-00578-1
  29. Gagnon MF, Penheiter AR, Harris F, Sadeghian D, Johnson SH, Karagouga G, McCune A, Zepeda-Mendoza C, Greipp PT, Xu X, et al. Unraveling the genomic underpinnings of unbalanced MYC break-apart FISH results using whole genome sequencing analysis. Blood Cancer J. 2023;13(1):190.  https://doi.org/10.1038/s41408-023-00967-8
  30. Pohar-Marinsek Z, Bracko M, Lavrencak J, Us-Krasovec M. DNA ploidy as a prognostic factor in rhabdomyosarcoma. Analysis of 35 cases with image cytometry. Anal Quant Cytol Histol. 2003;25(4):235-242. 

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.